POS0287 A PHASE III, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED CLINICAL TRIAL TO COMPARE BAT1806/BIIB800, A PROPOSED TOCILIZUMAB BIOSIMILAR, WITH TOCILIZUMAB REFERENCE PRODUCT IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE THERAPY

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 81; p. 388
Main Authors Leng, X., Leszczynski, P., Jeka, S., Liu, S., Liu, H., Miakisz, M., Gu, J., Kilasonia, L., Stanislavchuk, M., Yang, X., Zhou, Y., Dong, Q., Mitroiu, M., Addison, J., Zeng, X.
Format Journal Article
LanguageEnglish
Published 01.06.2022
Online AccessGet full text

Cover

More Information
ISSN:0003-4967
DOI:10.1136/annrheumdis-2022-eular.515